• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从除颤器降级至心脏再同步治疗起搏器的中期可行性及安全性

Mid-term feasibility and safety of downgrade procedure from defibrillator to pacemaker with cardiac resynchronization therapy.

作者信息

Ogano Michio, Iwasaki Yu-Ki, Tsuboi Ippei, Kawanaka Hidekazu, Tajiri Masaharu, Takagi Hisato, Tanabe Jun, Shimizu Wataru

机构信息

Department of Cardiovascular Medicine, Shizuoka Medical Center, 762-1 Nagasawa, Shimizu, Sunto Shizuoka 4110906, Japan.

Department of Cardiovascular Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo, Tokyo 1138603, Japan.

出版信息

Int J Cardiol Heart Vasc. 2018 Dec 29;22:78-81. doi: 10.1016/j.ijcha.2018.12.012. eCollection 2019 Mar.

DOI:10.1016/j.ijcha.2018.12.012
PMID:30619931
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6312857/
Abstract

BACKGROUNDS

Some patients who undergo implantation of cardiac resynchronization therapy with defibrillator (CRT-D) survive long enough, thus requiring CRT-D battery replacement. Defibrillator therapy might become unnecessary in patients who have had significant clinical improvement and recovery of left ventricular ejection fraction (LVEF) after CRT-D implantation.

METHODS

Forty-nine patients who needed replacement of a CRT-D battery were considered for exchange of CRT-D for cardiac resynchronization therapy with pacemaker (CRT-P) if they met the following criteria: LVEF >45%; the indication for an implantable cardioverter defibrillator was primary prevention at initial implantation and no appropriate implantable cardioverter defibrillator therapy was documented after initial implantation of the CRT-D.

RESULTS

Seven patients (14.2%) were undergone a downgrade from CRT-D to CRT-P without any complications. No ventricular tachyarrhythmic events were observed during a mean follow-up of 39.7 ± 21.1 months and there was no significant change in LVEF between before and 1 year after device replacement (53.5% ± 6.2% vs. 56.4% ± 7.3%,  = 0.197).

CONCLUSIONS

This study confirmed mid-term feasibility and safety of downgrade from CRT-D to CRT-P alternative to conventional replacement with CRT-D.

摘要

背景

一些接受心脏再同步治疗除颤器(CRT-D)植入的患者存活时间足够长,因此需要更换CRT-D电池。对于在CRT-D植入后临床有显著改善且左心室射血分数(LVEF)恢复的患者,除颤治疗可能不再必要。

方法

49例需要更换CRT-D电池的患者,如果符合以下标准,则考虑将CRT-D更换为心脏再同步治疗起搏器(CRT-P):LVEF>45%;植入式心律转复除颤器的适应证为初始植入时的一级预防,且在CRT-D初始植入后未记录到适当的植入式心律转复除颤器治疗。

结果

7例患者(14.2%)从CRT-D降级为CRT-P,无任何并发症。在平均39.7±21.1个月的随访期间,未观察到室性快速心律失常事件,设备更换前和更换后1年LVEF无显著变化(53.5%±6.2%对56.4%±7.3%,P=0.197)。

结论

本研究证实了从CRT-D降级为CRT-P替代传统CRT-D更换的中期可行性和安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfc7/6312857/be3b6ea7e6f5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfc7/6312857/be3b6ea7e6f5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfc7/6312857/be3b6ea7e6f5/gr1.jpg

相似文献

1
Mid-term feasibility and safety of downgrade procedure from defibrillator to pacemaker with cardiac resynchronization therapy.从除颤器降级至心脏再同步治疗起搏器的中期可行性及安全性
Int J Cardiol Heart Vasc. 2018 Dec 29;22:78-81. doi: 10.1016/j.ijcha.2018.12.012. eCollection 2019 Mar.
2
Appropriate implantable cardioverter-defibrillator interventions in cardiac resynchronization therapy-defibrillator (CRT-D) patients undergoing device replacement: time to downgrade from CRT-D to CRT-pacemaker? Insights from real-world clinical practice in the DECODE CRT-D analysis.心脏再同步治疗除颤器(CRT-D)患者更换器械时的适当植入式心律转复除颤器干预:是否需要从 CRT-D 降级为 CRT-起搏器?DECODE CRT-D 分析中的真实临床实践见解。
Europace. 2018 Sep 1;20(9):1475-1483. doi: 10.1093/europace/eux323.
3
Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial.心脏再同步治疗中左心室射血分数的正常化与室性心律失常和临床结局的风险:来自多中心自动除颤器植入试验与心脏再同步治疗(MADIT-CRT)试验的结果。
Circulation. 2014 Dec 23;130(25):2278-86. doi: 10.1161/CIRCULATIONAHA.114.011283. Epub 2014 Oct 9.
4
Risk of Ventricular Tachyarrhythmic Events in Patients Who Improved Beyond Guidelines for a Defibrillator in MADIT-CRT.在 MADIT-CRT 中,那些改善程度超过除颤器指南建议的患者发生室性心律失常事件的风险。
JACC Clin Electrophysiol. 2019 Oct;5(10):1172-1181. doi: 10.1016/j.jacep.2019.08.009. Epub 2019 Oct 2.
5
Close connection between improvement in left ventricular function by cardiac resynchronization therapy and the incidence of arrhythmias in cardiac resynchronization therapy-defibrillator patients.心脏再同步治疗除颤器患者左心室功能改善与心律失常发生率的密切关系。
Eur J Heart Fail. 2010 Dec;12(12):1325-32. doi: 10.1093/eurjhf/hfq171. Epub 2010 Oct 5.
6
Association between left ventricular ejection fraction post-cardiac resynchronization treatment and subsequent implantable cardioverter defibrillator therapy for sustained ventricular tachyarrhythmias.心脏再同步化治疗后左心室射血分数与持续性室性心动过速/心室颤动的后续植入式心脏转复除颤器治疗的相关性。
Circ Arrhythm Electrophysiol. 2013 Apr;6(2):257-64. doi: 10.1161/CIRCEP.112.000214. Epub 2013 Feb 26.
7
Impact of the right ventricular lead position on clinical outcome and on the incidence of ventricular tachyarrhythmias in patients with CRT-D.右心室导线位置对 CRT-D 患者临床结局和室性心律失常发生率的影响。
Heart Rhythm. 2013 Dec;10(12):1770-7. doi: 10.1016/j.hrthm.2013.08.020. Epub 2013 Aug 22.
8
Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review.心脏再同步治疗诱导左心室功能恢复后,合适的植入式心律转复除颤器治疗减少:一项荟萃分析和系统评价
Eur Heart J. 2015 Nov 1;36(41):2780-9. doi: 10.1093/eurheartj/ehv373. Epub 2015 Aug 10.
9
Normalization of Left Ventricular Ejection Fraction and Incidence of Appropriate Antitachycardia Therapy in Patients With Implantable Cardioverter Defibrillator for Primary Prevention of Sudden Death.用于心源性猝死一级预防的植入式心脏转复除颤器患者的左心室射血分数正常化和恰当抗心动过速治疗的发生率。
J Card Fail. 2016 Feb;22(2):125-32. doi: 10.1016/j.cardfail.2015.10.015. Epub 2015 Nov 11.
10
The influence of left ventricular ejection fraction on the effectiveness of cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy).左心室射血分数对心脏再同步治疗效果的影响:MADIT-CRT(心脏再同步治疗的多中心自动除颤器植入试验)。
J Am Coll Cardiol. 2013 Mar 5;61(9):936-44. doi: 10.1016/j.jacc.2012.11.051.

引用本文的文献

1
Follow-up of CRT-D patients downgraded to CRT-P at the time of generator exchange.在发生器更换时降级为心脏再同步治疗-起搏器(CRT-P)的心脏再同步治疗-除颤器(CRT-D)患者的随访
Front Cardiovasc Med. 2023 Jun 15;10:1217523. doi: 10.3389/fcvm.2023.1217523. eCollection 2023.
2
Adding clinical value with coronary flow assessment in hypertrophic obstructive cardiomyopathy.肥厚型梗阻性心肌病冠状动脉血流评估的临床价值
Int J Cardiol Heart Vasc. 2020 Apr 4;27:100512. doi: 10.1016/j.ijcha.2020.100512. eCollection 2020 Apr.
3
Emergence of endocardium/epicardium flow gradient as novel risk biomarker in patients with hypertrophic cardiomyopathy.

本文引用的文献

1
To the Editor- The cost of cardiac resynchronization therapy generator replacement?致编辑——心脏再同步治疗发生器更换的费用?
Heart Rhythm. 2018 Mar;15(3):e35-e36. doi: 10.1016/j.hrthm.2017.12.008. Epub 2017 Dec 8.
2
Cost-effectiveness of a risk-stratified approach to cardiac resynchronisation therapy defibrillators (high versus low) at the time of generator change.在更换除颤器时,风险分层方法对心脏再同步治疗除颤器(高 vs 低)的成本效益。
Heart. 2018 Mar;104(5):416-422. doi: 10.1136/heartjnl-2017-311749. Epub 2017 Sep 29.
3
Predictors and outcomes of cardiac resynchronization therapy extended to the second generator.
心内膜/心外膜血流梯度作为肥厚型心肌病患者新型风险生物标志物的出现。
Int J Cardiol Heart Vasc. 2020 Jan 6;26:100467. doi: 10.1016/j.ijcha.2019.100467. eCollection 2020 Feb.
预测因素和第二代心脏再同步治疗的结果。
Heart Rhythm. 2017 Dec;14(12):1793-1800. doi: 10.1016/j.hrthm.2017.09.002. Epub 2017 Sep 14.
4
Multiple Comorbidities and Response to Cardiac Resynchronization Therapy: MADIT-CRT Long-Term Follow-Up.多种合并症与心脏再同步治疗反应:MADIT-CRT长期随访
J Am Coll Cardiol. 2017 May 16;69(19):2369-2379. doi: 10.1016/j.jacc.2017.03.531.
5
Predictors and long-term outcome of super-responders to cardiac resynchronization therapy.心脏再同步治疗超反应者的预测因素及长期预后
Clin Cardiol. 2017 May;40(5):292-299. doi: 10.1002/clc.22658. Epub 2017 Mar 14.
6
Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review.心脏再同步治疗诱导左心室功能恢复后,合适的植入式心律转复除颤器治疗减少:一项荟萃分析和系统评价
Eur Heart J. 2015 Nov 1;36(41):2780-9. doi: 10.1093/eurheartj/ehv373. Epub 2015 Aug 10.
7
Changes in Follow-Up Left Ventricular Ejection Fraction Associated With Outcomes in Primary Prevention Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Device Recipients.与一级预防植入式心脏复律除颤器和心脏再同步治疗设备接受者的预后相关的随访左心室射血分数变化
J Am Coll Cardiol. 2015 Aug 4;66(5):524-31. doi: 10.1016/j.jacc.2015.05.057.
8
Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial.心脏再同步治疗中左心室射血分数的正常化与室性心律失常和临床结局的风险:来自多中心自动除颤器植入试验与心脏再同步治疗(MADIT-CRT)试验的结果。
Circulation. 2014 Dec 23;130(25):2278-86. doi: 10.1161/CIRCULATIONAHA.114.011283. Epub 2014 Oct 9.
9
Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE).植入式心脏除颤器可改善接受心脏再同步治疗的轻度症状性心力衰竭患者的生存率:收缩性左心室功能障碍(REVERSE)重构长期随访分析。
Circ Arrhythm Electrophysiol. 2013 Dec;6(6):1163-8. doi: 10.1161/CIRCEP.113.000570. Epub 2013 Oct 14.
10
Normalization of left ventricular ejection fraction after cardiac resynchronization therapy also normalizes survival.心脏再同步治疗后左心室射血分数的正常化也使生存率正常化。
Pacing Clin Electrophysiol. 2013 Aug;36(8):970-7. doi: 10.1111/pace.12174. Epub 2013 May 29.